Rest Of Latin America Patient Derived Xenografts/PDX Models Market (2025-2030)
The Rest Of Latin America Patient Derived Xenografts/PDX Models Market was valued at $3.37 Million in 2025 and projected to reach to $4.72 Million by 2030, representing a compound annual growth rate of 7.0%. Rest Of Latin America's PDX Models market is positioned for steady growth as healthcare systems modernize and adopt advanced preclinical research methodologies.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Rest Of Latin America Patient Derived Xenografts/PDX Models Market Trends and Insights
- In 2025, Rest Of Latin America is estimated at USD 3.37 million, reflecting growing adoption of personalized medicine and preclinical research infrastructure across the region.
- By 2030, Rest Of Latin America is forecast to expand to USD 4.72 million, driven by increasing investment in oncology research and pharmaceutical development capabilities. The PDX market in Rest Of Latin America is characterized by emerging demand from academic institutions and contract research organizations seeking advanced tumor modeling solutions.
- Rest Of Latin America's growth trajectory, with a compound annual growth rate (CAGR) of 7.0% between 2025 and 2030, underscores the region's gradual but steady integration into global precision medicine networks.
- Rest Of Latin America benefits from rising healthcare expenditure and collaborative partnerships with international biotech firms, positioning the region as an emerging hub for translational cancer research..
Key Market Statistics
- CAGR (2025-2030) 7.0% CAGR
- Market Size, 2025 ~USD 3.37 Million
- Forecast, 2030 ~USD 4.72 Million
- Country Rest Of Latin America
Rest Of Latin America Patient Derived Xenografts/PDX Models Market Overview
Market Size & Growth :
Rest Of Latin America's PDX Models market is valued at USD 3.37 million in 2025, with a projected CAGR of 7% through 2030, reaching USD 4.72 million. This steady growth outpaces some mature markets but lags the global average of 12.5%, indicating emerging adoption potential.
Personalized Medicine Adoption :
Growing investment in personalized medicine and precision oncology across Rest Of Latin America is driving PDX model adoption. Healthcare institutions are increasingly recognizing the value of patient-derived xenografts for tailored treatment development and drug efficacy testing.
Preclinical Research Infrastructure :
Expanding research capabilities and laboratory infrastructure in Rest Of Latin America are enabling greater accessibility to PDX models. Regional biotech companies and academic institutions are building capacity for advanced preclinical testing and translational research.
Regional Market Dynamics :
Rest Of Latin America represents a developing segment with untapped potential compared to Brazil and Mexico. Increasing pharmaceutical partnerships and CRO investments signal growing market maturity and opportunities for PDX model commercialization in underserved countries.
Rest Of Latin America Patient Derived Xenografts/PDX Models Market Dynamics
- The region's 7% CAGR reflects increasing awareness of personalized medicine benefits and growing investment in oncology research infrastructure.
- Key drivers include rising cancer incidence, pharmaceutical company expansion, and collaboration between regional institutions and global biotech firms. By 2030, the market is expected to reach USD 4.72 million, supported by improved regulatory frameworks and increased funding for drug development.
- However, growth remains constrained by limited capital availability, smaller patient populations in individual countries, and competition from established markets.
- Strategic partnerships with international CROs and technology transfer initiatives will be critical to accelerating adoption and bridging the innovation gap..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Merck KGaA
- Thermo Fisher Scientific Inc.
- SANOFI
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- Rest Of Latin America's PDX market is valued at USD 3.37 million in 2025 and is projected to grow to USD 4.72 million by 2030 at a 7.0% CAGR.
- Rest Of Latin America demonstrates steady market expansion driven by increased oncology research funding and adoption of personalized medicine approaches.
- Rest Of Latin America's growth is supported by emerging academic research capabilities and partnerships with international contract research organizations.
- Rest Of Latin America represents a developing but strategically important market segment within the Latin American PDX landscape.
Patient Derived Xenografts/PDX Models Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | ORTHOTOPIC IMPLANTATION (Implantation Method) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 12.5% from 2025 to 2030 |
| Largest Segment | PDX MODELS (Model Type & Service) |
| Market Size Base Year (Billions) | ~USD 0.37 (2025) |
| Revenue Forecast (Billions) | ~USD 0.66 (2030) |
| Segments Covered | Model Type & Service, Type, Implantation Method |
Rest Of Latin America Patient Derived Xenografts/PDX Models Market Report Segmentation
3 segment dimensions are covered across the global market.
By Model Type & Service
- Pdx Models
- Pdx Services
By Type
- Cryopreservation Services
- Model Characterization Services
- Model Creation & Expansion Services
- Mouse Model
- Other Pdx Services
- Rat Model
By Implantation Method
- Orthotopic Implantation
- Other Implantation Methods
- Subcutaneous Implantation
Target Audience
- Pharmaceutical & Biotech Companies : Need market intelligence to guide R&D investments, preclinical outsourcing decisions, and regional expansion strategies in Rest Of Latin America. Understanding local PDX capabilities helps optimize drug development timelines and costs.
- Contract Research Organizations (CROs) : Require market sizing and growth forecasts to justify PDX service expansion in Rest Of Latin America. Data supports business case development, facility investment decisions, and competitive positioning against established CROs.
- Academic & Research Institutions : Need market context to secure funding, establish partnerships with industry, and justify PDX model infrastructure investments. Understanding regional demand helps align research capabilities with commercial opportunities.
- Healthcare Investors & Private Equity : Seek market growth potential and investment opportunities in Rest Of Latin America's emerging PDX ecosystem. Data supports due diligence, valuation analysis, and portfolio company strategy development in the region.
- Government & Healthcare Policy Makers : Need evidence-based insights on PDX market development to inform healthcare innovation policies, research funding priorities, and precision medicine initiatives specific to Rest Of Latin America.
Key Companies in the Rest Of Latin America Patient Derived Xenografts/PDX Models Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CHARLES RIVER LABORATORIES | United States | Public Company | Research Models and Services,Discovery and Safety Assessment,Manufacturing Solutions, |
| THE JACKSON LABORATORY | United States | Foundation/Charitable Institution | Mouse breeding & colony management,Phenotyping, efficacy testing & study-ready induced models,Genetic research services & bioinformatics, |
| INOTIV | United States | Public Company | Research Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software, |
| JSR CORPORATION | Japan | Private Company | Digital Solutions (lithography, photoresists, CMP, display, 3D printing),Plastics (ABS, AES, AS, ASA resins),Life Sciences (diagnostics, reagents, bioprocess, drug discovery support), |
| GENOWAY | France | Public Company | Custom mouse models (KO/KI, humanized, immune checkpoint),Custom rat models (KO/KI, immunodeficient, reconstituted),Custom cell lines (KO/KI, reporter, inducible), |
| BIOCYTOGEN PHARMACEUTICALS CO., LTD. | China | Public Company | Gene-Editing Services,Pharmacological Efficacy and Toxicology Services,Model Animals, |
| CHAMPIONS ONCOLOGY, INC. | United States | Public Company | Tumorgraft-based translational oncology services,Personalized cancer care / patient-specific Tumorgraft programs,Lumin Bioinformatics and data-driven software, |
| PHARMARON | China | Public Company | Laboratory Services,Chemical and Formulation Process Development and Manufacturing Services (Small Molecule CDMO),Clinical Research Services, |
| SYNGENE INTERNATIONAL LIMITED | India | Public Company | Discovery services (chemistry and biology),Development services (preclinical, CMC, clinical development),Manufacturing (API and drug product, including biologics), |
| LABCORP | United States | Public Company | Routine and preventive diagnostics (chemistry, hematology, urinalysis, wellness),Specialty and esoteric testing (genetic, oncology, infectious disease, women’s health),Biopharma laboratory services and clinical trial testing, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Food and Feed Testing,Environmental Testing,Biopharma Testing and Services, |
CHARLES RIVER LABORATORIES
Charles River Laboratories is a public company founded in 1947 and headquartered in the United States. With 19,000 employees, it operates as a major provider of preclinical and clinical laboratory services.
THE JACKSON LABORATORY
The Jackson Laboratory is a foundation-based charitable institution founded in 1929 in the United States. The organization employs 2,100 staff members and focuses on genetic research and related scientific services.
INOTIV
INOTIV is a public company founded in 1974 and based in the United States. The company operates with 1,996 employees and provides research and development services.
JSR CORPORATION
JSR Corporation is a private company founded in 1948 and headquartered in Japan. With 7,997 employees, the company operates across multiple business segments.
GENOWAY
GENOWAY is a public company founded in 1999 and based in France. The organization employs 157 staff members and operates in the biotechnology sector.
BIOCYTOGEN PHARMACEUTICALS CO., LTD.
BIOCYTOGEN PHARMACEUTICALS CO., LTD. is a public company founded in 2008 and based in China. The company employs 1,443 staff members and operates in the pharmaceutical and biotechnology sectors.
CHAMPIONS ONCOLOGY, INC.
Champions Oncology, Inc. is a public company founded in 1985 and based in the United States. The company employs 214 staff members and operates in the oncology research and services sector.
PHARMARON
PHARMARON is a public company founded in 2004 and based in China. With 25,088 employees, the company provides drug discovery and development services.
SYNGENE INTERNATIONAL LIMITED
Syngene International Limited is a public company founded in 1993 and headquartered in India. The organization employs 6,692 staff members and provides integrated drug discovery and development services.
LABCORP
LabCorp is a public company founded in 1995 and based in the United States. With 66,385 employees, it operates as a major provider of clinical laboratory and diagnostic services.
EUROFINS SCIENTIFIC
Eurofins Scientific is a public company founded in 1987 and headquartered in Luxembourg. The organization employs 65,694 staff members and provides laboratory testing and analytical services across multiple industries.
Reasons to Buy this Report
- Regional Market Sizing & Forecasts : Obtain precise market valuation for Rest Of Latin America (USD 3.37M in 2025) with country-level breakdowns and 5-year projections. Understand regional growth trajectories and identify high-potential markets within the segment for targeted expansion strategies.
- Competitive Landscape Analysis : Gain insights into key players, market share distribution, and competitive positioning specific to Rest Of Latin America. Identify partnership opportunities, acquisition targets, and white-space opportunities in underserved countries.
- Growth Driver Identification : Understand region-specific factors driving PDX adoption including regulatory changes, healthcare infrastructure investments, and pharmaceutical company activities. Benchmark against global trends to assess Rest Of Latin America's unique market dynamics.
- Investment & Expansion Strategy : Make informed decisions on market entry, resource allocation, and partnership development in Rest Of Latin America. Evaluate market maturity, capital requirements, and ROI potential compared to other emerging regions.
- Stakeholder Intelligence : Access detailed profiles of regional biotech companies, CROs, academic institutions, and pharmaceutical players. Understand their capabilities, research focus, and collaboration preferences to identify strategic partnership opportunities.
Frequently asked questions
What is the current market size of PDX models in Rest Of Latin America?
Rest Of Latin America's PDX market is estimated at USD 3.37 million in 2025, with expectations to reach USD 4.72 million by 2030.
What is the projected growth rate for Rest Of Latin America's PDX market?
Rest Of Latin America's PDX market is expected to grow at a compound annual growth rate (CAGR) of 7.0% from 2025 to 2030.
What factors are driving growth in Rest Of Latin America's PDX market?
Rest Of Latin America's market growth is driven by increased investment in oncology research, rising adoption of personalized medicine, and expanding academic research infrastructure.
Which institutions are key players in Rest Of Latin America's PDX market?
Rest Of Latin America's PDX market is primarily served by academic research institutions, contract research organizations, and emerging biotech companies focused on cancer research.
How does Rest Of Latin America compare to other Latin American markets?
Rest Of Latin America represents a developing segment within Latin America, with moderate growth rates reflecting emerging research capabilities and increasing international collaboration.
RESEARCH METHODOLOGY
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global PDX model market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the PDX model market. The secondary sources used for this study include World Health Organization (WHO), American Association for Cancer Research, American Association for Laboratory Animal Science, EurOPDX, European Animal Research Association, European Society for Medical Oncology, European Association for Cancer Research, Federation for Laboratory of Cell Therapy, International Journal of Non-Communicable Diseases, European Medicines Agency (EMA), Alliance for Regenerative Medicine (ARM); ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.
Secondary data were collected and analyzed to determine the overall size of the global PDX model market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate & validate the total size of the PDX model market. These methods were also used extensively to estimate the size of various market segments.
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
Patient-derived xenografts (PDXs) are models of cancer where the tissue or cells from a patient’s tumor are implanted into an immunodeficient or humanized mouse. These models have been used to grow cancer tissues after they were removed from a patient. The PDX model is an important tool for cancer research. It is used to study the biology of cancer, test the efficacy of new therapies, and predict the response to therapy in individual patients.
The study offers an in-depth analysis of the PDX model market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key PDX model product providers.
Stakeholders
- Pharmaceutical & biotechnology companies
- Contract research organizations (CROs)
- Academic & research institutes
- Preclinical and translational research centers
- Life science companies
- Regulatory bodies
- Contract development and manufacturing organizations (CDMOs)
- Cancer research consortia & foundations
- Venture capitalists & strategic investors
- Government associations
- Medical institutions & universities
- Hospitals & clinics
Report Objectives
- To define, describe, and forecast the PDX model market based on implantation method, type, tumor type, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall PDX model market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the PDX model market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as acquisitions, expansions, agreements, partnerships, and collaborations in the PDX model market
- To benchmark players within the PDX model market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
Get the Full Patient Derived Xenografts/PDX Models Market Report
Full forecast, segment splits, and company analysis for all Patient Derived Xenografts/PDX Models Market.
- Canada Patient Derived Xenografts/PDX Models Market
- US Patient Derived Xenografts/PDX Models Market
- Germany Patient Derived Xenografts/PDX Models Market
- UK Patient Derived Xenografts/PDX Models Market
- France Patient Derived Xenografts/PDX Models Market
- Italy Patient Derived Xenografts/PDX Models Market
- Spain Patient Derived Xenografts/PDX Models Market
- China Patient Derived Xenografts/PDX Models Market
- Japan Patient Derived Xenografts/PDX Models Market
- India Patient Derived Xenografts/PDX Models Market
- Australia Patient Derived Xenografts/PDX Models Market
- South Korea Patient Derived Xenografts/PDX Models Market
- Brazil Patient Derived Xenografts/PDX Models Market
- Mexico Patient Derived Xenografts/PDX Models Market
- UAE Patient Derived Xenografts/PDX Models Market
- Rest Of Europe Patient Derived Xenografts/PDX Models Market
- Rest Of Asia Pacific Patient Derived Xenografts/PDX Models Market
- Kingdom Of Saudi Arabia Patient Derived Xenografts/PDX Models Market
- Rest Of GCC Countries Patient Derived Xenografts/PDX Models Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report